Skip to main content

Table 2 Baseline characteristics of enrolled patients in each included study. Data are expressed as mean and standard deviation (SD) or frequency and percentage

From: Impact of Cotadutide drug on patients with type 2 diabetes mellitus: a systematic review and meta-analysis

Study ID Groups Number of patients Age mean ± SD Males (%) Body mass index (BMI)
(kg/m2)
Weight (kg) Race
White Black Asian American Indian or Alaska Native
P. Ambery et al. 2018 [6]
(MAD study)
MEDI0382 300 mcg 11 54.8 ± 6.8 7 (64%) 33.2 ± 4.2 99.7 ± 16.7 11 (100%) 0 0 0
placebo 19 57.7 ± 6 12 (63%) 31.2 ± 3.1 88.5 ± 11.4 19 (100%) 0 0 0
P. D. Ambery 2018 [15] MEDI0382 300 mcg 6 28.3 ± 5.9 6 (100%) 27.4 ± 2.8 - 6 (100%) 0 0 0
placebo 12 32.8 ± 9.1 12 (100%) 25.7 ± 2.4 - 11 (91.7%) 0 0 0
Rajaa Nahra 2021 [16] MEDI0382 300 mcg 256 56.3 ± 10.2 127 (94.6%) - - 252 (98.4%) 3 (1.2%) 1 (0.4%) 0
placebo 112 57.3 ± 9.5 57 (50.9%) - - 107 (95.5%) 0 1 (0.9%) 3 (2.7%)
NCT03645421 MEDI0382 300 mcg 15 57.5 ± 9.2 13 (86.7%) - - 0 0 15 (100%) 0
placebo 16 60 ± 8.6 13 (81%) - - 0 0 16 (100%) 0
NCT03596177 MEDI0382 300 mcg 19 59.5 ± 8.4 18 (94.7%) - - 18 (94.7%) 0 0 0
placebo 9 65.2 ± 7.2 7 (77.8%) - - 8 (88.9%) 1 (11.1%) 0 0
NCT03444584 MEDI0382 300 mcg 25 61 ± 8.2 15 (60%) - - 25 (100%) 0 0 0
placebo 24 58.4 ± 10 12 (50%) - - 24 (100%) 0 0 0
Parker 2020 [17] Cohort 1 MEDI0382 300 mcg 26 58.7 ± 8.5 19 (73%) 31.5 ± 3.5 95.6 ± 17.2 25 (96%) 0 0 0
placebo 13 - 9 (69%) 31.6 ± 3.8 93.8 ± 21 13 (100%) 0 0 0
Cohort 2 MEDI0382 300 mcg 20 61.9 ± 6 10 (50%) 31.1 ± 3.5 92.4 ± 8.7 20 (100%) 0 0 0
placebo 6 - 5 (83%) 31.2 ± 3.5 93.7 ± 9.6 6 (100%) 0 0 0
NCT03550378 MEDI0382 300 mcg 21 71.1 ± 7.4 12 (57.1%) - - 20 (95.2%) 0 0 0
placebo 20 70.9 ± 4.7 9 (45%) - - 20 (100%) 0 0 0